Company Overview and News

0
MDxHealth sluit licentieovereenkomst met Philips voor gebruik prostaatkanker-biomarker

2018-06-06 globenewswire
HERSTAL, BELGIË en NIJMEGEN, NEDERLAND, 6 juni 2018 - MDxHealth SA ('MdxHealth', of 'de "Onderneming'), (Euronext Brussel: MDXH.BR), mondiaal leidend in moleculaire diagnostiek voor urologische kankers, heeft een wereldwijde licentieovereenkomst gesloten met Koninklijke Philips N.V. ("Philips") ten aanzien van de rechten voor de productie en commercialisering door MDxHealth van een prognostische testkit met Philips' onlangs gevalideerde prognostische prostaatkanker-biomarker, fosfodiësterase-4D7 ("PDE4D7").
MDXH

0
MDxHealth annonce de licence avec Philips pour un biomarqueur du cancer de la prostate

2018-06-06 globenewswire
MDxHealth annonce la conclusion d'un contrat de licence mondial avec Philips pour un biomarqueur du cancer de la prostate
MDXH

0
MDxHealth launch agreement with Philips for prognostic prostate cancer biomarker

2018-06-06 globenewswire
HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, June 6, 2018 - MDxHealth SA ("MDxHealth, or the "Company"), (Euronext Brussels: MDXH.BR), today announces a worldwide licencing agreement with Koninklijke Philips N.V. ("Philips") for the rights to manufacture and market Philips' recently validated prognostic biomarker for prostate cancer, phosphodiesterase-4D7 ("PDE4D7"), as a prognostic test. The test is based on technology which was jointly developed by Philips Research and The University of Glasgow.
MDXH

0
Assemblée Générale Ordinaire des Actionnaires

2018-05-31 globenewswire
IRVINE, CA, et HERSTAL, BELGIQUE - Le 31 mai 2018 16.00 - MDxHealth SA (Euronext : MDXH), a tenu aujourd'hui son Assemblée Générale Annuelle des Actionnaires à Bruxelles. Les actionnaires ont approuvé tous les sujets à l'ordre du jour de l'Assemblée Générale Annuelle des Actionnaires, y compris les états financiers pour l'exercice social clôturé le 31 décembre 2017.
MDXH

0
Annual General Shareholders' Meeting

2018-05-31 globenewswire
IRVINE, CA, et HERSTAL, BELGIQUE - 16:00 CEST, May 31,2018 - MDxHealth SA (Euronext : MDXH), held today its Annual General Shareholders' Meeting in Brussels. The shareholders approved all agenda items of the Annual General Shareholders' Meeting, including the financial statements for the financial year ended December 31, 2017.
MDXH

0
MDxHealth (R): Presentation of New Data on MDxHealth's Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting

2018-05-22 globenewswire
Moderated posters and oral presentations feature clinical and health economic validations of SelectMDx, ConfirmMDx and prospective clinical validation of AssureMDx
MDXH

0
MDxHealth releases 2017 Annual Report

2018-04-27 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 17:45 CEST, April 27, 2018 - MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: MDXH.BR), today released its 2017 Annual Report and the invitation to its Annual General Shareholders' Meeting ("AGM") to be held on Thursday 31 May 2018 at 10.00 CEST, at Regus Brussels Zuid-Midi Railway Station, Avenue Fonsny 46, box 59, 1060 Brussels.
MDXH

0
Publicatie MDxHealth jaarverslag 2017

2018-04-27 globenewswire
HERSTAL, BELGIË EN NIJMEGEN, NEDERLAND - 27 april 2018 - MDxHealth SA ("MDxHealth, of de "Onderneming"), (Euronext: MDXH.BR), publiceerde vandaag haar jaarverslag 2017, alsmede de uitnodiging voor de Jaarlijkse Algemene Vergadering van Aandeelhouders ('AVA') te houden op donderdag 31 mei 2018 om 10.00 uur CEST, in het Regus Brussels Zuid-Midi Railway Station, Avenue Fonsny 46, vak 59, 1060 Brussel.
MDXH

0
MDxHealth publie le Rapport Annuel 2017

2018-04-27 globenewswire
IRVINE, CA, et HERSTAL, BELGIQUE - 17h45 CEST, vendredi 27 avril 2018 - MDxHealth SA (« MDxHealth », ou la « Société »), (Euronext : MDXH.BR), a publié aujourd'hui son Rapport Annuel 2017 et l'invitation à son Assemblée Générale d'Actionnaires (« AG ») qui se tiendra le jeudi 31 mai à 10h00 CEST, chez Regus Brussels Zuid-Midi Railway Station, Avenue Fonsny 46, boîte 59, 1060 Bruxelles.
MDXH

0
MDxHealth maakt positieve klinische ontwikkelingen voor ConfirmMDx bekend

2018-04-26 globenewswire
HERSTAL, BELGIË EN NIJMEGEN, NEDERLAND - 26 april 2018 - MDxHealth SA ("MDxHealth, of de "Onderneming"), (Euronext: MDXH.BR), wereldleider in moleculaire diagnostiek voor urologische kankers, maakt twee positieve ontwikkelingen bekend m.b.t. haar ConfirmMDx for Prostate Cancer test. De inclusie van ConfirmMDx in de 2018 Europese Associatie van Urologie (EAU) klinisch richtlijnen en de publicatie van een multicenter validatie van de test onder Afro-Amerikaanse mannen.
MDXH

0
MDxHealth annonce des mises à jour cliniques positives pour ConfirmMDx

2018-04-26 globenewswire
IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CEST, jeudi 26 avril 2018 - MDxHealth SA (Euronext : MDXH.BR) annonce aujourd'hui deux mises à jour cliniques positives concernant son test ConfirmMDx for Prostate Cancer.
MDXH

0
MDxHealth Announces Positive Clinical Updates for ConfirmMDx

2018-04-26 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 26, 2018 - MDxHealth SA (Euronext: MDXH.BR) today announces two positive clinical developments for its ConfirmMDx for prostate cancer test.
MDXH

0
MDxHealth publie ses résultats du premier trimestre 2018

2018-04-24 globenewswire
IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CEST, mardi 24 avril 2018 - MDxHealth SA (« MDxHealth », ou la « Société »), (Euronext : MDXH.BR), a publié aujourd'hui ses résultats pour le premier trimestre de l'année 2018, clos le 31 mars.
MDXH

0
MDxHealth Provides First Quarter 2018

2018-04-24 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 24, 2018 - MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: MDXH.BR), today issued its business update for the first quarter ended March 31, 2018.
MDXH

0
MDxHealth publiceert update over het eerste kwartaal van 2018

2018-04-24 globenewswire
HERSTAL, BELGIË EN NIJMEGEN, NEDERLAND - 24 april 2018 - MDxHealth SA ("MDxHealth, of de "Onderneming"), (Euronext: MDXH.BR), wereldleider in moleculaire diagnostiek voor urologische kankers, maakt de update over de eerste drie maanden van 2018 eindigend op 31 maart bekend.
MDXH

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

20h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

21h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...